missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human AKR1E2 (aa 105-168) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (44%), Rat (44%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-58123 (PA5-58123. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
The protein encoded by this gene is a member of the aldo-keto reductase superfamily. Members in this family are characterized by their structure (evolutionarily highly conserved TIM barrel) and function (NAD(P)H-dependent oxido-reduction of carbonyl groups). Transcripts of this gene have been reported in specimens of human testis. Alternative splicing results in multiple transcript variants.
Specifications
Specifications
| Accession Number | Q96JD6 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 83592 |
| Name | Human AKR1E2 (aa 105-168) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 1,5-anhydro-D-fructose reductase; AF reductase; Akr1cl2; Akr1e1; Akr1e2; AKRDC1; Aldo-keto reductase family 1 member C-like protein 2; aldo-keto reductase family 1 member E2; aldo-keto reductase family 1, member C-like 2; aldo-keto reductase family 1, member E1; aldo-keto reductase family 1, member E2; aldo-keto reductase loopADR; htAKR; hTSP; LoopADR; Testis aldo-keto reductase; Testis-specific protein |
| Common Name | AKR1E2 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction